4. 原発性側索硬化症 Primary lateral sclerosis Clinical trials / Disease details
臨床試験数 : 7 / 薬物数 : 17 - (DrugBank : 9) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 32
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-004798-99-DE (EUCTR) | 27/02/2013 | 27/12/2012 | Safety and Efficacy of SOD1 Inhibition By Pyrimethamine in Familial (ALS) | Safety and Efficacy of SOD1 Inhibition By Pyrimethamine in Familial (ALS) - Pyrimethamine In Familial ALS | Familial amyotrophic lateral sclerosis (FALS) MedDRA version: 14.1;Level: LLT;Classification code 10036704;Term: Primary lateral sclerosis;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Daraprim INN or Proposed INN: PYRIMETHAMINE | Weill Medical College of Cornell University | NULL | Not Recruiting | Female: yes Male: yes | 40 | United States;Germany;Italy |